Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics AML Express

NeoGenomics has launched AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia. The panel test, which is intended to be used in conjunction with patients' clinical features and other laboratory results, has a turnaround time of three to four days and includes genes selected for their clinical relevance in AML, including both DNA and RNA alterations. According to NeoGenomics, the assay aligns with the latest guidelines from the European LeukemiaNet, adopted by the National Comprehensive Cancer Network, and the World Health Organization Classification for Hematolymphoid Tumors.